SAN DIEGO, June 19 /PRNewswire-FirstCall/ -- Cardium Therapeutics (Amex: CXM) and its operating unit InnerCool Therapies announced today that InnerCool has entered into a exclusive commercialization agreement with N.G.C. Medical S.p.A., a leading Italian distributor of medical products. N.G.C. Medical primarily sells medical products to the intensive care, surgical and interventional cardiology markets. They also provide in-service management of surgical suites, intensive care units and interventional laboratories for a number of Italy's leading hospitals. The agreement covers InnerCool's CoolBlue(TM), a nurse-friendly and cost-effective surface cooling temperature modulation system, which was launched in the U.S. market during the fourth quarter 2007, as well as InnerCool's Celsius Control(TM) endovascular system and next-generation, high-performance RapidBlue(TM) system. Using N.G.C. Medical's marketing and sales force, sales of CoolBlue and RapidBlue consoles and disposables are expected to begin in Italy in the third quarter of 2008.
"We are pleased to have this distribution agreement with N.G.C.
Medical," stated Christopher J. Reinhard, Chairman and Chief Executive
Officer of Cardium Therapeutics and InnerCool Therapies. "This new Italian
partnership, along with our recent distribution agreements for Australia,
New Zealand, Germany, Switzerland and Austria are consistent with our
strategy of accelerating the growth of InnerCool's temperature modulation
business in a strategic, efficient and cost-effective manner by
establishing relationships with existing specialized intern
|SOURCE Cardium Therapeutics, Inc.|
Copyright©2008 PR Newswire.
All rights reserved